What moves, what doesn't, and how to plan around it.
Compound availability in this category is set by regulatory category placement, and it changes. This page explains the mechanism a clinic actually needs to understand, and tracks where the moving parts stand.
Last reviewed 2026-09-02
Availability is a regulatory outcome, not a supply problem
When a compound becomes hard to get in this category, the cause is usually not a shortage in the ordinary sense. It is that the substance's regulatory category has moved, and compounding facilities have adjusted what they are willing to prepare in response. Understanding that distinction is the difference between a clinic that plans and a clinic that reacts.
The two paths, and what each one permits
A 503(a) pharmacy compounds for one identified patient against a valid prescription. It cannot prepare product in advance to sit on a clinic's shelf. A 503(b) outsourcing facility is FDA-registered, compounds in batches under CGMP requirements, and may supply for office use in defined circumstances. Which path is available for a given compound shapes your inventory model, your scheduling and your patient experience.
Bulk-substance categories are the lever
For substances without an approved drug application behind them, whether they may be compounded at all runs through FDA bulk-substance evaluation. Category placement is what a facility looks at when deciding whether to prepare something. A substance can move between categories, and when it does, catalogs change — sometimes quickly, and rarely with useful notice to the clinics downstream.
This is why the program treats menu breadth and inventory conservatism as design decisions rather than caution. A clinic whose economics rest on one compound has taken a regulatory position without meaning to.
What a clinic should actually do about it
- Carry a category rather than a compound, so a substitution path exists before you need one.
- Size par levels to demonstrated demand, not to projected demand.
- Keep the patient conversation at the category level, so a substitution is not experienced as a broken promise.
- Confirm what each partner pharmacy currently prepares before publishing a menu, rather than working from a catalog you were sent months ago.
- Treat any compound's availability as revocable, including the stable ones.
Where the moving parts stand.
The shortage-driven window that permitted broad compounding of these substances closed, and enforcement activity in this lane has been substantial. Marketing compounded GLP-1s is the single highest-exposure activity in the category.
Position as understood in 2026
These have moved between bulk-substance categories, which is what makes their availability volatile. Plan menus so neither carries the economics alone.
Position as understood in 2026
Compoundable, though sermorelin in particular carries a heavier documentation and attestation burden than the rest of the category. That is a workflow cost, not a sourcing one.
Position as understood in 2026
Has occupied a quieter regulatory lane than most of the category, which is why it frequently anchors a starter menu. Stable is not guaranteed.
Position as understood in 2026
A formal advisory review of Category 2 substances was scheduled for mid-2026. We are not publishing an outcome for it, because publishing an unverified regulatory result is worse than publishing nothing. Confirm the current position with the partner pharmacy or your own counsel before making a menu decision that depends on it.
Unresolved as at this page's last review
This page is a plain-English explanation of how compounding categories work, plus a dated status board. It is not legal advice, and it is not a substitute for confirming a compound's current position with the preparing pharmacy or with your own regulatory counsel. Where an outcome is not confirmed, this page says so rather than estimating it.
Regulatory questions.
Why did a compound we were carrying suddenly become unavailable?
Does Revival decide what is compoundable?
Can you tell us what will be available next year?
Is a compounded peptide FDA-approved?
Your patients are already asking about peptides.Make sure your clinic is ready to answer.
Build and launch your peptide program with Revival RX Partners in 90 days.
Important
- Revival RX Partners is a consulting and sourcing partner. It is not a pharmacy, does not compound or dispense medication, and does not practice medicine or provide medical advice.
- All medications are dispensed by licensed partner pharmacies against valid prescriptions issued by your clinic's licensed prescribers.
- Compounded peptides are not FDA-approved products. Availability, regulatory status, and pharmacy capability vary by compound and by state, and are subject to change.
- Nothing on this page is a guarantee of revenue, patient volume, or clinical outcomes. Revenue figures shown are illustrative and generated from values you enter.